Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The investigators will determine the feasibility, safety and efficacy of intravenous sodium
bicarbonate in reducing progression to overt acute renal failure in patients with the
systemic inflammatory response syndrome, and low urine output or early acute renal impairment
as defined by serum neutrophil gelatinase-associated lipocalin (NGAL).